Perspectives on current practices and future research directions in alpha-1 antitrypsin deficiency
Therapeutic Advances in Respiratory Disease · 2026-10 · 20
DOI: 10.1177/17534666261494062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 28.10.2026. Verfasst von Noel G McElvaney und 13 weiteren Autor:innen. Beteiligte Einrichtung: Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Pulmonary Disease, Chronic Obstructive, alpha 1-Antitrypsin. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring.
Abstract (Originalsprache)
Alpha-1 antitrypsin deficiency (AATD) is a complex genetic condition that predisposes individuals to develop respiratory diseases, including chronic obstructive pulmonary disease (COPD). The clinical presentation of AATD varies between patients and disease progression is difficult to predict, presenting challenges for diagnosis and disease management. Additionally, a lack of AATD awareness among physicians has contributed to underdiagnosis and low testing rates. Consequently, there is a need to improve diagnostic algorithms to identify underlying AATD in respiratory patients. Strategies to increase physician awareness and promote systematic testing of patients with COPD may also improve testing rates. Additionally, implementing offsite sample testing may ease the testing process and alleviate the need for patients to travel to genetic testing facilities. Use of patient registries has enabled many advances in our understanding of AATD and continues to be an important asset for research. Advances in genetic sequencing technologies and data analysis capabilities, including artificial intelligence, are likely to improve our understanding of AATD and the variance observed between patients. Increasingly, the significance of different variants will be a topic for future research. Specific treatment for AATD is available and real-world evidence demonstrates a survival benefit of receiving intravenous alpha-1 antitrypsin (AAT) therapy; however, its precise mechanisms of clinical efficacy remain incompletely understood. This review summarises key advances in the genetics, clinical presentation, diagnosis, and treatment of AATD, while highlighting the benefits of AAT therapy and remaining research gaps. Despite the availability of specific treatment, assessing which patients to treat can be challenging, as many factors need to be considered. Individualisation of treatment decisions is crucial, supported by close monitoring and early initiation of treatment where appropriate. Improving access to AAT therapy, including self-administration options, may further enhance patient care. Emerging AATD therapies offer hope for disease modification, improved outcomes, and expanded treatment options for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
- Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
- Pneumology Department, Vall D'Hebron University Hospital, Vall D'Hebron Institut de Recerca, Vall D'Hebron Hospital Campus, Health Care Provider of the European Reference Network on Rare Respiratory Diseases (ERN LUNG),…
- School of Health Sciences, University of Birmingham, Birmingham, UK.
- Department of Pulmonology, University Hospital and University of Zurich, Zurich, Switzerland.
- Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany.
ORCID-Profile: Marc Miravitlles, Miriam Barrecheguren, Joachim H Ficker
Förderung
- CSL Behring
Zitieren
APA
McElvaney, N. G., Chorostowska-Wynimko, J., Miravitlles, M., Turner, A. M., Clarenbach, C. F., Herth, F. J. F., Barrecheguren, M., Costa, F., Ficker, J. H., Mornex, J. F., Idzko, M., Koczulla, A. R., Trudzinski, F. C., & Vianello, A. (2026). Perspectives on current practices and future research directions in alpha-1 antitrypsin deficiency. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261494062
Vancouver
McElvaney NG, Chorostowska-Wynimko J, Miravitlles M, Turner AM, Clarenbach CF, Herth FJF, et al. Perspectives on current practices and future research directions in alpha-1 antitrypsin deficiency. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261494062
BibTeX
@article{McElvaney2026,
author = {McElvaney, Noel G and Chorostowska-Wynimko, Joanna and Miravitlles, Marc and Turner, Alice M and Clarenbach, Christian F and Herth, Felix J F and Barrecheguren, Miriam and Costa, Filipa and Ficker, Joachim H and Mornex, Jean-François and Idzko, Marco and Koczulla, Andreas R and Trudzinski, Franziska C and Vianello, Andrea},
title = {Perspectives on current practices and future research directions in alpha-1 antitrypsin deficiency},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
volume = {20},
doi = {10.1177/17534666261494062}
}
EUVIMED